Literature DB >> 21404358

Exploring sequence requirements for C₃/C₄ carboxylate recognition in the Pseudomonas aeruginosa cephalosporinase: Insights into plasticity of the AmpC β-lactamase.

Sarah M Drawz1, Magdalena Taracila, Emilia Caselli, Fabio Prati, Robert A Bonomo.   

Abstract

In Pseudomonas aeruginosa, the chromosomally encoded class C cephalosporinase (AmpC β-lactamase) is often responsible for high-level resistance to β-lactam antibiotics. Despite years of study of these important β-lactamases, knowledge regarding how amino acid sequence dictates function of the AmpC Pseudomonas-derived cephalosporinase (PDC) remains scarce. Insights into structure-function relationships are crucial to the design of both β-lactams and high-affinity inhibitors. In order to understand how PDC recognizes the C₃/C₄ carboxylate of β-lactams, we first examined a molecular model of a P. aeruginosa AmpC β-lactamase, PDC-3, in complex with a boronate inhibitor that possesses a side chain that mimics the thiazolidine/dihydrothiazine ring and the C₃/C₄ carboxylate characteristic of β-lactam substrates. We next tested the hypothesis generated by our model, i.e. that more than one amino acid residue is involved in recognition of the C₃/C₄ β-lactam carboxylate, and engineered alanine variants at three putative carboxylate binding amino acids. Antimicrobial susceptibility testing showed that the PDC-3 β-lactamase maintains a high level of activity despite the substitution of C₃/C₄ β-lactam carboxylate recognition residues. Enzyme kinetics were determined for a panel of nine penicillin and cephalosporin analog boronates synthesized as active site probes of the PDC-3 enzyme and the Arg349Ala variant. Our examination of the PDC-3 active site revealed that more than one residue could serve to interact with the C₃/C₄ carboxylate of the β-lactam. This functional versatility has implications for novel drug design, protein evolution, and resistance profile of this enzyme.
Copyright © 2011 The Protein Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21404358      PMCID: PMC3104225          DOI: 10.1002/pro.612

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  67 in total

1.  Recognition and resistance in TEM beta-lactamase.

Authors:  Xiaojun Wang; George Minasov; Jesús Blázquez; Emilia Caselli; Fabio Prati; Brian K Shoichet
Journal:  Biochemistry       Date:  2003-07-22       Impact factor: 3.162

Review 2.  Psychrophilic enzymes: hot topics in cold adaptation.

Authors:  Georges Feller; Charles Gerday
Journal:  Nat Rev Microbiol       Date:  2003-12       Impact factor: 60.633

Review 3.  Emerging carbapenemases: a global perspective.

Authors:  Timothy R Walsh
Journal:  Int J Antimicrob Agents       Date:  2010-11       Impact factor: 5.283

4.  Mutant of Pseudomonas aeruginosa 18S that synthesizes type Id beta-lactamase constitutively.

Authors:  F Flett; N A Curtis; M H Richmond
Journal:  J Bacteriol       Date:  1976-09       Impact factor: 3.490

5.  Isolation and properties of an inducible and a constitutive beta-lactamase from Pseudomonas aeruginosa.

Authors:  M Berks; K Redhead; E P Abraham
Journal:  J Gen Microbiol       Date:  1982-01

6.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

7.  Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 beta-lactamase: defining a unique family of class C enzymes.

Authors:  Kristine M Hujer; Nashaat S Hamza; Andrea M Hujer; Federico Perez; Marion S Helfand; Christopher R Bethel; Jodi M Thomson; Vernon E Anderson; Miriam Barlow; Louis B Rice; Fred C Tenover; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

8.  Multiple global suppressors of protein stability defects facilitate the evolution of extended-spectrum TEM β-lactamases.

Authors:  Nicholas G Brown; Jeanine M Pennington; Wanzhi Huang; Tulin Ayvaz; Timothy Palzkill
Journal:  J Mol Biol       Date:  2010-10-16       Impact factor: 5.469

9.  Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group.

Authors:  H Goossens
Journal:  Clin Microbiol Infect       Date:  2003-09       Impact factor: 8.067

10.  Nanomolar inhibitors of AmpC beta-lactamase.

Authors:  Federica Morandi; Emilia Caselli; Stefania Morandi; Pamela J Focia; Jesús Blázquez; Brian K Shoichet; Fabio Prati
Journal:  J Am Chem Soc       Date:  2003-01-22       Impact factor: 15.419

View more
  29 in total

1.  Kinetics of avibactam inhibition against Class A, C, and D β-lactamases.

Authors:  David E Ehmann; Haris Jahic; Philip L Ross; Rong-Fang Gu; Jun Hu; Thomas F Durand-Réville; Sushmita Lahiri; Jason Thresher; Stephania Livchak; Ning Gao; Tiffany Palmer; Grant K Walkup; Stewart L Fisher
Journal:  J Biol Chem       Date:  2013-08-02       Impact factor: 5.157

2.  Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234.

Authors:  Krisztina M Papp-Wallace; Nhu Q Nguyen; Michael R Jacobs; Christopher R Bethel; Melissa D Barnes; Vijay Kumar; Saralee Bajaksouzian; Susan D Rudin; Philip N Rather; Satish Bhavsar; Tadiparthi Ravikumar; Prasad K Deshpande; Vijay Patil; Ravindra Yeole; Sachin S Bhagwat; Mahesh V Patel; Focco van den Akker; Robert A Bonomo
Journal:  J Med Chem       Date:  2018-04-20       Impact factor: 7.446

3.  Insights into β-lactamases from Burkholderia species, two phylogenetically related yet distinct resistance determinants.

Authors:  Krisztina M Papp-Wallace; Magdalena A Taracila; Julian A Gatta; Nozomi Ohuchi; Robert A Bonomo; Michiyoshi Nukaga
Journal:  J Biol Chem       Date:  2013-05-08       Impact factor: 5.157

4.  Negative Epistasis and Evolvability in TEM-1 β-Lactamase--The Thin Line between an Enzyme's Conformational Freedom and Disorder.

Authors:  Eynat Dellus-Gur; Mikael Elias; Emilia Caselli; Fabio Prati; Merijn L M Salverda; J Arjan G M de Visser; James S Fraser; Dan S Tawfik
Journal:  J Mol Biol       Date:  2015-05-22       Impact factor: 5.469

5.  Avibactam and inhibitor-resistant SHV β-lactamases.

Authors:  Marisa L Winkler; Krisztina M Papp-Wallace; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

6.  Inhibition of Acinetobacter-Derived Cephalosporinase: Exploring the Carboxylate Recognition Site Using Novel β-Lactamase Inhibitors.

Authors:  Emilia Caselli; Chiara Romagnoli; Rachel A Powers; Magdalena A Taracila; Alexandra A Bouza; Hollister C Swanson; Kali A Smolen; Francesco Fini; Bradley J Wallar; Robert A Bonomo; Fabio Prati
Journal:  ACS Infect Dis       Date:  2017-12-08       Impact factor: 5.084

7.  β-Lactamase inhibition by 7-alkylidenecephalosporin sulfones: allylic transposition and formation of an unprecedented stabilized acyl-enzyme.

Authors:  Elizabeth A Rodkey; David C McLeod; Christopher R Bethel; Kerri M Smith; Yan Xu; Weirui Chai; Tao Che; Paul R Carey; Robert A Bonomo; Focco van den Akker; John D Buynak
Journal:  J Am Chem Soc       Date:  2013-12-03       Impact factor: 15.419

8.  Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.

Authors:  Marisa L Winkler; Elizabeth A Rodkey; Magdalena A Taracila; Sarah M Drawz; Christopher R Bethel; Krisztina M Papp-Wallace; Kerri M Smith; Yan Xu; Jeffrey R Dwulit-Smith; Chiara Romagnoli; Emilia Caselli; Fabio Prati; Focco van den Akker; Robert A Bonomo
Journal:  J Med Chem       Date:  2013-02-04       Impact factor: 7.446

9.  Interactions of oximino-substituted boronic acids and β-lactams with the CMY-2-derived extended-spectrum cephalosporinases CMY-30 and CMY-42.

Authors:  Stathis D Kotsakis; Emilia Caselli; Leonidas S Tzouvelekis; Efi Petinaki; Fabio Prati; Vivi Miriagou
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

10.  Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes.

Authors:  Lin Lin; Brandon Tan; Paul Pantapalangkoor; Tiffany Ho; Andrea M Hujer; Magdalena A Taracila; Robert A Bonomo; Brad Spellberg
Journal:  Vaccine       Date:  2012-11-12       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.